Document is current
Any future updates will be listed below
-
Authors
Deng, Siyou
Wang, Qi
Li, Yueping
Zhang, Ruijie
Li, Jinjie
Zhang, Yujie
Cai, Yixin
Sun, Wei
Chang, Jiang
Zhang, Ni
Zhang, Li https://orcid.org/0000-0002-8433-2402
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05028231 at ClinicalTrials.govDocuments that mention this clinical trial
Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma
https://doi.org/10.1007/s00262-025-04099-9
Neoadjuvant immunotherapy (PD-1) combined with chemotherapy for locally advanced thoracic esophageal carcinoma (EC): A single-arm, open-label, phase II study.
https://doi.org/10.1200/jco.2024.42.16_suppl.4075
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82172825)
- License Information
-
More Information
Article History
Received: 2 April 2025
Accepted: 27 May 2025
First Online: 18 June 2025
Declarations
:
: The authors declare no competing interests.
: This study was performed in accordance with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Tongji Hospital, Huazhong University of Science and Technology (Approval No. 2019-S910). The trial was registered at ClinicalTrials.gov (Identifier: NCT05028231).
: Written informed consent was obtained from all individual participants included in the study.
: Not applicable. This manuscript does not contain any individual person’s data in any form (including images or videos).
